Jump to a section

BPC-157 before-and-after results

SHOULDER PAIN

Less pressing pain

5–6 → 2–3 /10

By week 3. [1]

POST-EXERCISE ACHING

Shorter soreness

48 → 24 hours

By week 2. [1]

ORAL CAPSULE EXAMPLE

Comfortable lifting

45 lb curls

Without pain by day 45. [4]

Individual experiences; results vary.

Shoulder pain fell by week three

Pressing pain dropped from 5–6/10 to 2–3/10. Post-exercise aching shortened from roughly 48 to 24 hours during week two. Internal shoulder rotation improved during week three; progress then plateaued around the middle of week four.

Reported amount
250 mcg daily
Course
6 weeks
Starting problem
14 months of shoulder pain; MRI showed mild supraspinatus tendinopathy.
Before5–6 / 10
Week 32–3 / 10

By week six, resting pain was nearly absent, but loading still caused discomfort. Moderate training and mobility exercises continued throughout.

Individual account: u/Timely_Ad8989. Pain scores were self-assessed. [1]

Elbow recovery over six weeks

Movement improved first; pain continued to fall over the following weeks. The first elbow-tendinitis course used BPC-157 alone at 250 mcg twice daily for six weeks.

Weeks 2–3

First noticeable improvement and easier movement.

Week 4

Nearly pain-free.

Week 6

About 95% less pain and full mobility.

Individual account: kisaj on AnabolicMinds. The percentage is a personal estimate. A later BPC-157/TB-500 course concerned a separate episode. [2]

Knee swelling settled within days

Intermittent swelling subsided during the first days of BPC-157 use. The three-week update also included treadmill activity and two 5 km runs.

Week 1 amount
250 mcg daily
Later amount
250 mcg twice daily
Alongside use
Mobility work and exercise

The improvement preceded any proposed switch to Wolverine, so it belongs to the BPC-only period.

Individual account: u/floppy4237, three-week update. [3]

Oral BPC-157: lifting and digestive changes

Pain-free 45 lb curls by day 45

Arm pain eased around week three; 45 lb curls became comfortable by day 45. The pain had persisted despite an earlier three-month gym break. Moderate, high-repetition exercise and progressive loading continued during the course.

Capsule strength: 500 mcg. The complete daily schedule was not specified clearly. The outcome was pain-free lifting; a suspected biceps or tendon tear was not confirmed by imaging.

Individual capsule account: u/ParagonMonday. [4]

Better digestion during a two-month oral course

Digestive comfort improved, alongside early fatigue and unexplained muscle soreness. The amount was 500 mcg daily for two months; the oral formulation was not clearly identified as capsules. The connection between BPC-157 and the soreness remained uncertain.

Individual oral account: u/ghostride1. [5]

Human studies: knee pain and bladder symptoms

11 / 12Knee-pain improvement after BPC-157 alone

Direct injection into the knee joint.

10 / 12Complete bladder-symptom resolution

Specialist treatment around inflamed bladder areas.

Knee pain: 11 of 12 BPC-only patients improved. Three of four receiving BPC-157 plus thymosin beta-4 also improved. Follow-up relied on retrospective reports, with no placebo group. [6]

Bladder pain: a 2024 pilot involved 12 women with interstitial cystitis. Ten described complete symptom resolution; the other two described roughly 80% improvement. The study had no control group. [7]

These results concern the named clinical procedures, not retail capsules, nasal spray or pen use.

Clinical follow-up: weeks and months

7 / 12Knee-pain relief lasting 6–12 months

BPC-157-only group. [11]

2 weeksEarliest bladder-symptom improvement

Urgency and urinary frequency improved first. [12]

6 weeksFollow-up bladder examination

Cystoscopy after the specialist procedure. [12]

Knee-pain relief did not last equally long for everyone. Seven of the 12 BPC-only patients were in the six-to-twelve-month relief category; the remaining five were outside that category. In the bladder study, most symptom questionnaires were collected four to six months after treatment. The six-week milestone refers to the scheduled bladder examination. [11] [12]

Results recorded in 1,039 patients’ medical notes

SEPTEMBER 2026 PREPRINT · NOT PEER REVIEWED

1,039Documented BPC-157 users
354With a recorded symptom-response direction
279With improvement recorded

Among the 354 with a recorded response, 79% improved, 16% had no change and 5% worsened. The remaining 685 users had no directional response documented. These percentages therefore describe the subset with outcome notes. [10]

AI-assisted review of routine medical notes, with physician validation of samples. About half used another therapeutic agent; dose, formulation and follow-up were not standardized. This observational preprint cannot isolate BPC-157’s effect from other treatment or natural recovery.

No improvement after a six-week combination course

Elbow, forearm, wrist and shoulder symptoms showed no noticeable improvement. Gym recovery and strength also remained unchanged. A back flare occurred during the course.

Reported BPC-157 amount
250 mcg twice daily
Reported TB-500 amount
1,500 mcg, three times weekly
Duration
6 weeks

Individual combination account: u/Main-Pea-912. [8]

BPC-157 and TB-500: Wolverine ingredients and reported use →

Results timeline: days to six weeks

Time pointChangeExample
Within daysKnee swelling settled.BPC-only account [3]
Week 2Post-exercise aching shortened from 48 to 24 hours.Shoulder account [1]
Weeks 2–3Elbow movement and discomfort began improving.Elbow account [2]
Week 3Pressing pain fell to 2–3/10; arm-pain improvement during capsule use became clearer.Separate shoulder and arm accounts [1] [4]
Week 4Elbow pain was nearly absent; shoulder improvement plateaued.Separate elbow and shoulder accounts [2] [1]
Week 6 / day 45Elbow mobility was restored; 45 lb curls were pain-free in the capsule example. The combination course produced no improvement.Three separate outcomes [2] [4] [8]

Selected individual timelines, not an average response schedule.

Results after stopping BPC-157

Shoulder improvement remained nine weeks later

Lower pain and better movement persisted nine weeks after the six-week course. Recovery was self-rated at roughly 85–90%, with continued mobility exercises and moderate loading.

Follow-up from u/Timely_Ad8989. [1]

Digestive symptoms returned during weeks three and four

Urgency and cramping returned after an initially manageable two weeks off. This involved oral BPC-157 in a non-capsule formulation and a history of IBS. Symptoms approached their earlier severity.

Individual oral-use follow-up: u/TrueBelievingMoron. [9]

Human clinical trials: oral absorption and injury healing

Registered studyWhat it testsResult status
Oral PCO-02
NCT02637284
A Phase I plan for 42 healthy adults: safety and absorption of BPC-157 tablets compared with placebo.No results posted. The protocol does not provide a capsule-versus-injection effectiveness comparison. [13]
Acute hamstring strain
NCT07437547
120 planned participants; subcutaneous BPC-157 or placebo for 14 days alongside the same rehabilitation program. Endpoints include MRI injury volume and return to sport.Listed as recruiting; primary completion estimated for February 2027. The registered timetable is not an observed recovery result. [14]

Registry snapshot: 5 November 2026. Participant targets and planned measurements are separate from completed study outcomes.

Benefits for specific injuries → · Back to the complete BPC-157 guide →

THE PRACTICAL QUESTIONS

Questions & answers.

How soon can BPC-157 results appear?

The examples range from knee swelling settling within days to shoulder and elbow changes during weeks two and three. A separate combination course produced no improvement after six weeks. These are individual timelines, not a predicted response.

How much did the shoulder and elbow examples use?

The shoulder account used 250 mcg daily for six weeks. The first elbow course used BPC-157 alone at 250 mcg twice daily for six weeks. These figures describe those accounts.

Did oral BPC-157 produce before-and-after results?

The capsule example reached pain-free 45 lb curls by day 45. Another oral account described improved digestive comfort during two months, together with fatigue and muscle soreness. The products and circumstances differed.

Can pain improve before recovery is complete?

Yes. At six weeks, the shoulder example had almost no resting pain but still had discomfort under load. Pain relief alone does not confirm a repaired tendon or cartilage.

Does adding TB-500 guarantee a better result?

No. The six-week BPC-157/TB-500 example had no improvement in the targeted symptoms. Adding a second ingredient does not guarantee stronger pain relief or faster recovery.

Do BPC-157 results last after stopping?

The shoulder improvement remained nine weeks later while mobility work continued. In a separate oral-use example, digestive urgency and cramps returned during weeks three and four off. Lasting improvement is not consistent across these accounts.

Sources & batch documents14 references · expand to read
  1. u/Timely_Ad8989: Original six-week shoulder experience ↗
  2. kisaj: Original elbow course, AnabolicMinds discussion (February 2024) ↗
  3. u/floppy4237: Original knee-swelling update at three weeks ↗
  4. u/ParagonMonday: Original oral-capsule arm-pain account at day 45 ↗
  5. u/ghostride1: Original two-month oral experience ↗
  6. FDA (2026): Scientific evaluation and human knee-study summary ↗
  7. Lee, Walker & Ayadi (2024): Interstitial cystitis pilot study ↗
  8. u/Main-Pea-912: Original six-week BPC-157 + TB-500 nonresponse ↗
  9. u/TrueBelievingMoron: Original digestive-symptom report four weeks after stopping oral use ↗
  10. Venkatakrishnan et al. (September 2026): BPC-157 use and outcomes in clinical notes; preprint, not peer reviewed ↗
  11. Lee & Padgett (2021): Original knee-pain paper, including duration of relief in Table 4 ↗
  12. Lee, Walker & Ayadi: Original bladder-pain study reproduced by a study author; onset and follow-up details ↗
  13. ClinicalTrials.gov NCT02637284: Oral PCO-02 Phase I safety and pharmacokinetics trial; no results posted ↗
  14. ClinicalTrials.gov NCT07437547: BPC-157 for acute hamstring strain; recruiting study record ↗